Eisai

Helsinn and Eisai will continue to co-promote and distribute Aloxi (palonosetron HCl) injection for the prevention of chemotherapy-induced nausea and vomiting (CINV).

The move comes as the companies have revised the agreement for their (CINV) franchise.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

As per the agreed terms, the company’s US affiliate Helsinn Therapeutics will also obtain exclusive rights to promote and sell Akynzeo (netupitant / palonosetron), its oral fixed dose combination product for the prevention of CINV.

“We are proud of our past collaboration with Helsinn and are pleased to continue to partner on making aloxi available to the oncology community.”

The akynzeo is an oral fixed combination of palonosetron and netupitant indicated for the prevention of CINV.

The palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

See Also:

Currently approved in both the US and Europe, akynzeo targets two critical signalling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Helsinn vice chairman and CEO Riccardo Braglia said: "The acquisition of exclusive rights to akynzeo is an important milestone for Helsinn as it marks our commercial expansion in the US.

"We are excited to have this unique opportunity with akynzeo while still maintaining our long-standing partnership with Eisai for aloxi."

Aloxi injection 0.25mg is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

The 20mcg/kg (max 1.5mg) aloxi injection is indicated in patients above one month and up to 17 years of age.

Eisai president and COO Shaji Procida said: "This revised arrangement will enable Eisai to focus on aloxi and our growing oncology franchise.

"We are proud of our past collaboration with Helsinn and are pleased to continue to partner on making aloxi available to the oncology community."

Image: Eisai head office in Tokyo. Photo: courtesy of KW.